Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
DRD2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ASENAPINE | ? unclear | Mechanistic | DGIdb | |
| MEPHENTERMINE | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL LACTATE | ↓ inhibits | Mechanistic | DGIdb | |
| BREXPIPRAZOLE | ↑ activates | Mechanistic | DGIdb | |
| ANALGESIC AGENT | ? unclear | Mechanistic | DGIdb | |
| AXITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| RG-1530 | ↓ inhibits | Mechanistic | DGIdb | |
| LOXAPINE SUCCINATE | ↓ inhibits | Mechanistic | DGIdb | |
| QUETIAPINE FUMARATE | ↓ inhibits | Mechanistic | DGIdb | |
| PROCHLORPERAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| APOMORPHINE | ↑ activates | Mechanistic | DGIdb | |
| PRAMIPEXOLE | ? unclear | Mechanistic | DGIdb | |
| THIETHYLPERAZINE MALEATE | ↓ inhibits | Mechanistic | DGIdb | |
| IBCASERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| FAMITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| SOXATALTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| SUMANIROLE | ↑ activates | Mechanistic | 9.0 nM (Ki) | DGIdb |
| DOCARPAMINE | ? unclear | Mechanistic | DGIdb | |
| PALIPERIDONE | ↓ inhibits | Mechanistic | DGIdb | |
| PRIDOPIDINE | ~ modulates | Mechanistic | DGIdb | |
| OLANZAPINE | ↓ inhibits | Mechanistic | 20.0 nM (Ki) | DGIdb |
| PEGDINETANIB | ↓ inhibits | Mechanistic | DGIdb | |
| RISPERIDONE | ↓ inhibits | Mechanistic | DGIdb | |
| PERGOLIDE MESYLATE | ↑ activates | Mechanistic | DGIdb | |
| LISURIDE | ? unclear | Mechanistic | 0.5 nM (Ki) | DGIdb |
| ZICRONAPINE | ? unclear | Mechanistic | DGIdb | |
| CLEBOPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| LAZERTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| REMOXIPRIDE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CABERGOLINE | ↑ activates | Mechanistic | DGIdb | |
| JNJ-37822681 | ↓ inhibits | Mechanistic | DGIdb | |
| ERGOT ALKALOIDS | ? unclear | Mechanistic | DGIdb | |
| (-)-STEPHOLIDINE | ? unclear | Mechanistic | DGIdb | |
| SARIZOTAN HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| 5-OH-DPAT | ? unclear | Mechanistic | DGIdb | |
| LITHIUM | ? unclear | Mechanistic | DGIdb | |
| DIHYDROERGOTOXINE | ? unclear | Mechanistic | DGIdb | |
| REMOXIPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| BROMPERIDOL | ↓ inhibits | Mechanistic | DGIdb | |
| PHENTOLAMINE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 427 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NCGC607 | ? unclear | Mechanistic | DGIdb | |
| AFEGOSTAT | ? unclear | Mechanistic | 60.0 nM (IC50) | DGIdb |
| GENTIAN VIOLET CATION | ? unclear | Mechanistic | DGIdb | |
| VELAGLUCERASE ALFA | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CIRSIMARITIN | ? unclear | Mechanistic | DGIdb | |
| DOMIPHEN BROMIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1169388 | ? unclear | Mechanistic | DGIdb | |
| 2,3-DIHYDROXY-6,7-DICHLOROQUINOXALINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL579837 | ? unclear | Mechanistic | DGIdb | |
| METITEPINE | ? unclear | Mechanistic | DGIdb | |
| TALIGLUCERASE ALFA | ? unclear | Mechanistic | DGIdb | |
| APTIGANEL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL588327 | ? unclear | Mechanistic | DGIdb | |
| MIGALASTAT | ? unclear | Mechanistic | DGIdb | |
| CHLORHEXIDINE GLUCONATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL528181 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1379900 | ? unclear | Mechanistic | DGIdb | |
| L 755507 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL73711 | ? unclear | Mechanistic | DGIdb | |
| DNQX | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL408500 | ? unclear | Mechanistic | DGIdb | |
| CASTANOSPERMINE | ? unclear | Mechanistic | DGIdb | |
| SULFANITRAN | ? unclear | Mechanistic | DGIdb | |
| AMBROXOL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL578928 | ? unclear | Mechanistic | DGIdb | |
| PHLORETIN | ? unclear | Mechanistic | DGIdb | |
| GENISTEIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL603154 | ? unclear | Mechanistic | DGIdb | |
| AFEGOSTAT TARTRATE | ~ modulates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL529939 | ? unclear | Mechanistic | DGIdb | |
| ISOLIQUIRITIGENIN | ? unclear | Mechanistic | DGIdb | |
| TRICHOSTATIN A | ? unclear | Mechanistic | DGIdb | |
| EBSELEN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL3350088 | ↓ inhibits | Mechanistic | 150.0 nM (Ki) | ChEMBL |
| CHEMBL3350093 | ↓ inhibits | Mechanistic | 550.0 nM (Ki) | ChEMBL |
| CHEMBL3350086 | ↓ inhibits | Mechanistic | 25.1 nM (Ki) | ChEMBL |
| CHEMBL3350089 | ↓ inhibits | Mechanistic | 100.0 nM (Ki) | ChEMBL |
| CHEMBL3350092 | ↓ inhibits | Mechanistic | 1.2 nM (Ki) | ChEMBL |
| CHEMBL469844 | ↓ inhibits | Mechanistic | 200.0 nM (Ki) | ChEMBL |
Showing top 40 of 156 agents ranked by evidence tier.
LRRK2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LRRK2 INHIBITOR 6 [PMID: 40353293] | ↓ inhibits | Mechanistic | DGIdb | |
| LIRADASERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| ADAVOSERTIB | ? unclear | Mechanistic | DGIdb | |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| NIK INHIBITOR 12F | ↓ inhibits | Mechanistic | DGIdb | |
| DCLK1-IN-1 | ↓ inhibits | Mechanistic | DGIdb | |
| DACTOLISIB | ? unclear | Mechanistic | DGIdb | |
| VANDETANIB | ? unclear | Mechanistic | 1995.26 nM (Ki) | DGIdb |
| LRRK2-IN-1 | ↓ inhibits | Mechanistic | DGIdb | |
| DOVITINIB | ? unclear | Mechanistic | 1500.0 nM (Kd) | DGIdb |
| BOS172722 | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2204495 | ? unclear | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | 630.96 nM (Ki) | DGIdb |
| MLI-2 | ↓ inhibits | Mechanistic | DGIdb | |
| PALBOCICLIB | ? unclear | Mechanistic | 2511.89 nM (Ki) | DGIdb |
| ENTRECTINIB | ? unclear | Mechanistic | 2511.89 nM (Ki) | DGIdb |
| HG-10-102-01 | ↓ inhibits | Mechanistic | DGIdb | |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL379975 | ? unclear | Mechanistic | DGIdb | |
| GSK2646264 | ↓ inhibits | Mechanistic | DGIdb | |
| PD166285 | ? unclear | Mechanistic | DGIdb | |
| GNE-9605 | ↓ inhibits | Mechanistic | DGIdb | |
| PELERASERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| ALISERTIB | ? unclear | Mechanistic | 794.33 nM (Ki) | DGIdb |
| AST-487 | ? unclear | Mechanistic | 950.0 nM (Kd) | DGIdb |
| PF-06447475 | ↓ inhibits | Mechanistic | DGIdb | |
| URMC-099 | ↓ inhibits | Mechanistic | DGIdb | |
| PICTILISIB | ? unclear | Mechanistic | DGIdb | |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| XMD-12 | ↓ inhibits | Mechanistic | DGIdb | |
| EB-42486 | ↓ inhibits | Mechanistic | DGIdb | |
| PF-06454589 | ↓ inhibits | Mechanistic | DGIdb | |
| NIK SMI1 | ↓ inhibits | Mechanistic | DGIdb | |
| JAK3 INHIBITOR VI | ↓ inhibits | Mechanistic | DGIdb | |
| TTT-3002 | ↓ inhibits | Mechanistic | DGIdb | |
| XL01126 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 8 [PMID: 17480064] | ? unclear | Mechanistic | DGIdb | |
| ILORASERTIB | ? unclear | Mechanistic | DGIdb | |
| CENISERTIB | ? unclear | Mechanistic | 0.631 nM (Ki) | DGIdb |
| FASUDIL | ? unclear | Mechanistic | 1995.26 nM (Ki) | DGIdb |
Showing top 40 of 206 agents ranked by evidence tier.
MAOB
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SAFINAMIDE | ↓ inhibits | Mechanistic | 450.0 nM (Ki) | DGIdb |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1927670 | ? unclear | Mechanistic | DGIdb | |
| MOCLOBEMIDE | ↓ inhibits | Mechanistic | 100000.0 nM (Ki) | DGIdb |
| CHEMBL:CHEMBL1927684 | ? unclear | Mechanistic | DGIdb | |
| SELEGILINE | ↓ inhibits | Mechanistic | 970.0 nM (Ki) | DGIdb |
| BIFEMELANE | ↓ inhibits | Mechanistic | DGIdb | |
| MEBANAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| MELATONIN | ? unclear | Mechanistic | DGIdb | |
| PARGYLINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602260 | ? unclear | Mechanistic | DGIdb | |
| ISOCARBOXAZID | ↓ inhibits | Mechanistic | DGIdb | |
| SEROTONIN | ? unclear | Mechanistic | DGIdb | |
| [18F]FLUORORASAGILINE | ? unclear | Mechanistic | DGIdb | |
| RASAGILINE | ↓ inhibits | Mechanistic | 700.0 nM (Ki) | DGIdb |
| CHEMBL:CHEMBL1642672 | ? unclear | Mechanistic | DGIdb | |
| PHENOXYPROPAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| LAZABEMIDE | ↓ inhibits | Mechanistic | 84.0 nM (Ki) | DGIdb |
| NIALAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1813518 | ? unclear | Mechanistic | DGIdb | |
| SAFINAMIDE MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| COBALAMIN | ? unclear | Mechanistic | DGIdb | |
| PHENELZINE | ↓ inhibits | Mechanistic | DGIdb | |
| RASAGILINE TARTRATE | ↓ inhibits | Mechanistic | DGIdb | |
| RALFINAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SELEGILINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| VITAMIN K3 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2088303 | ? unclear | Mechanistic | DGIdb | |
| TRANYLCYPROMINE | ↓ inhibits | Mechanistic | DGIdb | |
| PARGYLINE | ? unclear | Mechanistic | 1800.0 nM (Ki) | DGIdb |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| MOFEGILINE | ? unclear | Mechanistic | DGIdb | |
| INDANTADOL | ? unclear | Mechanistic | DGIdb | |
| NAPHTHOQUINONE | ? unclear | Mechanistic | DGIdb | |
| METHAMPHETAMINE | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL DECANOATE | ? unclear | Mechanistic | DGIdb | |
| PHENELZINE SULFATE | ↓ inhibits | Mechanistic | DGIdb | |
| IPRONIAZID | ↓ inhibits | Mechanistic | 7540.0 nM (IC50) | DGIdb |
| LINEZOLID | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602466 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 218 agents ranked by evidence tier.
SLC6A3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ALTROPANE I-123 | ? unclear | Mechanistic | DGIdb | |
| BUPROPION HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DEXMETHYLPHENIDATE | ↓ inhibits | Mechanistic | DGIdb | |
| AMPHETAMINE ADIPATE | ? unclear | Mechanistic | DGIdb | |
| DEXTROAMPHETAMINE SACCHARATE | ? unclear | Mechanistic | DGIdb | |
| LIAFENSINE | ↓ inhibits | Mechanistic | DGIdb | |
| LISDEXAMFETAMINE DIMESYLATE | ? unclear | Mechanistic | DGIdb | |
| METHAMPHETAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| SIBUTRAMINE | ? unclear | Mechanistic | DGIdb | |
| METHYLPHENIDATE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| 3,4-METHYLENEDIOXYMETHAMPHETAMINE | ? unclear | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| DEXTROAMPHETAMINE ADIPATE | ? unclear | Mechanistic | DGIdb | |
| METYROSINE | ? unclear | Mechanistic | DGIdb | |
| ANESTHETIC AGENT | ? unclear | Mechanistic | DGIdb | |
| SERTRALINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| BENZTROPINE | ? unclear | Mechanistic | 312.0 nM (IC50) | DGIdb |
| BICIFADINE | ↓ inhibits | Mechanistic | DGIdb | |
| ALTROPANE | ? unclear | Mechanistic | DGIdb | |
| DASOTRALINE | ↓ inhibits | Mechanistic | DGIdb | |
| DISULFIRAM | ? unclear | Mechanistic | DGIdb | |
| AMITIFADINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| AMPHETAMINE ASPARTATE | ? unclear | Mechanistic | DGIdb | |
| NICOTINE POLACRILEX | ? unclear | Mechanistic | DGIdb | |
| SPIROGLUMIDE | ? unclear | Mechanistic | DGIdb | |
| HINOKININ | ? unclear | Mechanistic | DGIdb | |
| DIETHYLPROPION HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SERDEXMETHYLPHENIDATE CHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PHENTERMINE RESIN | ? unclear | Mechanistic | DGIdb | |
| PSEUDOEPHEDRINE | ? unclear | Mechanistic | DGIdb | |
| PHENMETRAZINE | ? unclear | Mechanistic | DGIdb | |
| CENTANAFADINE | ↓ inhibits | Mechanistic | DGIdb | |
| BUPRENORPHINE | ? unclear | Mechanistic | DGIdb | |
| PYROVALERONE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SERDEXMETHYLPHENIDATE | ↓ inhibits | Mechanistic | DGIdb | |
| PHENMETRAZINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| FENCAMFAMIN | ? unclear | Mechanistic | DGIdb | |
| IOFLUPANE I-123 | ? unclear | Mechanistic | DGIdb | |
| PHENDIMETRAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| MAZINDOL | ↓ inhibits | Mechanistic | 42.6 nM (IC50) | DGIdb |
Showing top 40 of 176 agents ranked by evidence tier.
SNCA
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL:CHEMBL1521156 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL599100 | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| LEVOKETOCONAZOLE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL450802 | ? unclear | Mechanistic | DGIdb | |
| CALCDPWW | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580727 | ? unclear | Mechanistic | DGIdb | |
| PRASINEZUMAB | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL505670 | ? unclear | Mechanistic | DGIdb | |
| CONGO RED FREE ACID | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL548540 | ? unclear | Mechanistic | DGIdb | |
| GARDENIN | ? unclear | Mechanistic | DGIdb | |
| 6-AZAURIDINE | ? unclear | Mechanistic | DGIdb | |
| PARAROSANILINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL534353 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2094833 | ? unclear | Mechanistic | DGIdb | |
| GENTIAN VIOLET CATION | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2094567 | ? unclear | Mechanistic | DGIdb | |
| 2-CHLOROADENOSINE-5-TRIPHOSPHATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL442906 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1534035 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1526167 | ? unclear | Mechanistic | DGIdb | |
| PP2 | ? unclear | Mechanistic | DGIdb | |
| MYCOPHENOLATE | ? unclear | Mechanistic | DGIdb | |
| ALTENUSIN | ? unclear | Mechanistic | DGIdb | |
| GW305074X | ? unclear | Mechanistic | DGIdb | |
| INDENEBART | ? unclear | Mechanistic | DGIdb | |
| ABT702 | ? unclear | Mechanistic | DGIdb | |
| CINPANEMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LICARIN A | ? unclear | Mechanistic | DGIdb | |
| LITHOCHOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| CAFFEIC ACID PHENETHYL ESTER | ? unclear | Mechanistic | DGIdb | |
| CHEMBL1594514 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1411318 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1379677 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1476741 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1565212 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1331245 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1411120 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1459532 | ~ modulates | Mechanistic | ChEMBL |
Showing top 40 of 221 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METYROSINE | ↓ inhibits | Mechanistic | DGIdb | |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| SAPONIN | ? unclear | Mechanistic | DGIdb | |
| PROSAVIN | ? unclear | Mechanistic | DGIdb | |
| OPIATE | ? unclear | Mechanistic | DGIdb | |
| FLUTAMIDE | ? unclear | Mechanistic | DGIdb | |
| 3-IODOBENZYLGUANIDINE | ? unclear | Mechanistic | DGIdb | |
| PRASTERONE | ? unclear | Mechanistic | DGIdb | |
| METHYLPHENIDATE | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT INTERFERON | ? unclear | Mechanistic | DGIdb | |
| SERTRALINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| 3-IODOTYROSINE | ↓ inhibits | Mechanistic | DGIdb | |
| 3-CHLOROTYROSINE | ↓ inhibits | Mechanistic | DGIdb | |
| SAPROPTERIN | ? unclear | Mechanistic | DGIdb | |
| DOXYCYCLINE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| TRIAMTERENE | ? unclear | Mechanistic | DGIdb | |
| ALPHA-TOCOPHEROL | ? unclear | Mechanistic | DGIdb | |
| Α-PROPYLDOPACETAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TYROSINE | ? unclear | Mechanistic | DGIdb | |
| PHENYLALANINE | ? unclear | Mechanistic | DGIdb | |
| METHADONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ANTIESTROGEN | ? unclear | Mechanistic | DGIdb | |
| EPOETIN ALFA | ? unclear | Mechanistic | DGIdb | |
| CHEMBL27559 | ↓ inhibits | Mechanistic | 42000.0 nM (IC50) | ChEMBL |
| CHEMBL330274 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| R-N-PROPYLNORAPOMORPHINE | ↓ inhibits | Mechanistic | 300.0 nM (IC50) | ChEMBL |
| CHEMBL283489 | ↓ inhibits | Mechanistic | 87000.0 nM (IC50) | ChEMBL |
| IOTYROSINE | ↓ inhibits | Mechanistic | 720.0 nM (IC50) | ChEMBL |
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by rigidity, tremor, postural instability, bradykinesia, and autonomic dysfunction. It is a common movement disorder worldwide. Motor impairments in PD patients are not limited to the muscles of the extremities; the n...
Parkinson's disease (PD) affects \~1% of people over 60 years old, is highly disabling and represents a large economic burden. While dopaminergic medications effectively treat motor symptoms early in the disease, most patients develop complications, including motor fluctuations and dyskinesias, whic...
The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are: Does the tailored amino acid s...
Background: \- Parkinson s disease (PD) causes slow movement, stiffness, and tremor. It results from the loss of a brain chemical called dopamine. PD gets worse over time, but researchers do not fully understand why the brain cells that produce dopamine stop working or die in people with PD. This s...
Parkinson's disease is frequently associated with impaired postural control, balance deficits, trunk misalignment, altered proprioception, and an increased risk of falls. These impairments may contribute to reduced mobility, pain, loss of independence, and decreased quality of life. Although rehabil...
This study aims to determine the effects of a motor-cognitive exercise intervention, delivered in the home environment using eHealth methods, among people with Parkinson's disease. The intervention will support and motivate motor training, combined with cognitive training, aimed at attentional and e...
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Pos...
Background: \- Glial cell line-derived neurotrophic factor (GDNF) is a chemical that may help protect and strengthen brain cells that produce dopamine. Dopamine is a chemical that affects brain function. People with Parkinson's disease (PD) have problems producing dopamine in the brain. Researchers...
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn ...
The purpose of this project is to use transcranial magnetic stimulation (TMS) to explore the state of excitability of corticocortical and corticofugal (cortex to spinal cord, cortex to brainstem to spinal cord) pathways that project to muscles that control the legs and trunk in people with Parkinson...
Background: * Previous studies have given researchers information on how the brain controls movement, how people learn to make fine, skilled movements, and why some people have movement disorders. However, further research is needed to learn more about the causes of most movement disorders, such as...
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic pr...
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Based on the high-quality Parkinson's disease cohort population and biological sample database in the early stage of the team, multi-dimensional intelligent wearable device technology and machine learning were used to screen and classify digital biomarkers in the prodromal PD cohort, early PD cohort...
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Searched directly from “Parkinson's Disease” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."